Antibiotics Market Value Expected To Reach US$ 57.1 Billion By 2027: Acumen Research and Consulting
18 mars 2021 10h05 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Antibiotics Market–Global Industry Analysis, Market Size, Opportunities and...
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
17 mars 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
11 mars 2021 07h05 HE
|
Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
Recro to Present at H.C. Wainwright Global Life Science Conference
02 mars 2021 07h00 HE
|
Recro Pharma, Inc.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports Fourth Quarter and Year End 2020 Financial Results
26 févr. 2021 07h00 HE
|
Recro Pharma, Inc.
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...
Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
23 févr. 2021 16h05 HE
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Amendment to Athyrium Credit Facility
23 févr. 2021 07h00 HE
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan
22 févr. 2021 08h05 HE
|
Avid Bioservices, Inc
Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue...
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
19 févr. 2021 16h05 HE
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Strengthens Leadership Team With Key Executive and Board Appointments
11 févr. 2021 07h00 HE
|
Recro Pharma, Inc.
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial OfficerRecent Appointments, including CEO David Enloe, Provide...